Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Time to Sell?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped down prior to trading on Tuesday. The stock had previously closed at $21.79, but opened at $20.37. Chugai Pharmaceutical shares last traded at $21.30, with a volume of 32,124 shares.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Chugai Pharmaceutical currently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Down 5.2%

The stock has a market cap of $69.05 billion, a PE ratio of 22.80 and a beta of 0.60. The company has a fifty day moving average of $20.76 and a 200-day moving average of $24.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.27 EPS for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The business had revenue of $2.54 billion during the quarter, compared to the consensus estimate of $2.29 billion. As a group, research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 1.00 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.